SIM
SAGE

SummerHaven Investment Management’s Sage Therapeutics SAGE Stock Holding History

SummerHaven Investment Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-18,130
Closed -$586K – 256
2022
Q2 		$586K Hold
18,130
– – 0.4% 144
2022
Q1 		$600K Buy
18,130
+815
+5% +$30.6K 0.34% 176
2021
Q4 		$737K Hold
17,315
– – 0.4% 160
2021
Q3 		$767K Buy
+17,315
New +$794K 0.45% 155

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SummerHaven Investment Management's SAGE Position: Q3 2022 in Review

SummerHaven Investment Management sold out of Sage Therapeutics (SAGE) in Q3 2022, closing a stake of 18,130 shares — an estimated $586K sold.

SummerHaven Investment Management first reported a position in SAGE in Q3 2021 and held it in 4 quarters. The position peaked at $767K in Q3 2021. 200 funds tracked by Wall St. Rank hold SAGE as of Q3 2022.

  • SummerHaven Investment Management reported no remaining Sage Therapeutics position as of Q3 2022 after selling out during the quarter.
  • SummerHaven Investment Management sold 18,130 Sage Therapeutics shares in Q3 2022, an estimated $586K.
  • SummerHaven Investment Management first reported a position in Sage Therapeutics in Q3 2021 and held it in 4 quarters.
  • SummerHaven Investment Management's Sage Therapeutics position peaked at $767K in Q3 2021.
  • 200 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2022.

Based on SummerHaven Investment Management's 13F filing for Q3 2022, filed 20 Oct 2022.